Cargando…

Predicting Ovarian/Breast Cancer Pathogenic Risks of Human BRCA1 Gene Variants of Unknown Significance

High-throughput sequencing is gaining popularity in clinical diagnoses, but more and more novel gene variants with unknown clinical significance are being found, giving difficulties to interpretations of people's genetic data, precise disease diagnoses, and the making of therapeutic strategies...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Hui-Heng, Xu, Hongyan, Hu, Hongbo, Ma, Zhanzhong, Zhou, Jie, Liang, Qingyun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8062186/ https://www.ncbi.nlm.nih.gov/pubmed/33937409 http://dx.doi.org/10.1155/2021/6667201

Ejemplares similares

Clinical significance of variants of unknown significances in BRCA genes
por: Choi, Min Chul
Publicado: (2019)

The Clinical Significance of Unknown Sequence Variants in BRCA Genes
por: Calò, Valentina, et al.
Publicado: (2010)

Assessing the pathogenicity of BRCA1/2 variants of unknown significance: Relevance and challenges for breast cancer precision medicine
por: De Paolis, Elisa, et al.
Publicado: (2023)

BRCA1 and BRCA2 Testing through Next Generation Sequencing in a Small Cohort of Italian Breast/Ovarian Cancer Patients: Novel Pathogenic and Unknown Clinical Significance Variants
por: Concolino, Paola, et al.
Publicado: (2019)

Germline BRCA1 and BRCA2 deleterious mutations and variants of unknown clinical significance associated with breast/ovarian cancer: a report from North India
por: Mehta, Anurag, et al.
Publicado: (2018)

BRCA 1/BRCA 2 Pathogenic/Likely Pathogenic Variant Patients with Breast, Ovarian, and Other Cancers
por: Osman, K., et al.
Publicado: (2023)

High-throughput functional evaluation of BRCA2 variants of unknown significance
por: Ikegami, Masachika, et al.
Publicado: (2020)

Analysis of BRCA1/2 variants of unknown significance in the prospective Korean Hereditary Breast Cancer study
por: Kim, Joo Heung, et al.
Publicado: (2021)

The influence of BRCA variants of unknown significance on cancer risk management decision-making
por: Chern, Jing-Yi, et al.
Publicado: (2019)

Prevalence and oncologic outcomes of BRCA1/2 mutation and variant of unknown significance in epithelial ovarian carcinoma patients in Korea
por: Seo, Jun Hyeong, et al.
Publicado: (2019)

Ovarian Cancer With Breast Metastasis and Two Pathogenic Variants of BRCA1 Gene
por: Kowsarnia, Saeedeh, et al.
Publicado: (2021)

From a variant of unknown significance to pathogenic: Reclassification of a large novel duplication in BRCA2 by high‐throughput sequencing
por: van Luttikhuizen, Jana Lisa, et al.
Publicado: (2019)

Are DDX41 variants of unknown significance and pathogenic variants created equal?
por: Xie, Zhuoer, et al.
Publicado: (2023)

Author Correction: Analysis of BRCA1/2 variants of unknown significance in the prospective Korean Hereditary Breast Cancer study
por: Kim, Joo Heung, et al.
Publicado: (2023)

Comparison of Clinical Outcomes of BRCA1/2 Pathologic Mutation, Variants of Unknown Significance, or Wild Type Epithelial Ovarian Cancer Patients
por: Eoh, Kyung Jin, et al.
Publicado: (2017)

Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants
por: Barnes, Daniel R., et al.
Publicado: (2020)

Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2
por: O’Mahony, Denise G., et al.
Publicado: (2023)

Trans-activation-based risk assessment of BRCA1 BRCT variants with unknown clinical significance
por: Langerud, Jonas, et al.
Publicado: (2018)

Reclassification of Five BRCA1/2 Variants with Unknown Significance Using Complex Functional Study
por: Bozsik, Anikó, et al.
Publicado: (2022)

Relevance of pathogenicity prediction tools in human RYR1 variants of unknown significance
por: Hoppe, Kerstin, et al.
Publicado: (2021)

Evaluation of copy-number variants as modifiers of breast and ovarian cancer risk for BRCA1 pathogenic variant carriers
por: Walker, Logan C, et al.
Publicado: (2017)

Germline variants profiling of BRCA1 and BRCA2 in Chinese Hakka breast and ovarian cancer patients
por: Zhang, Yunuo, et al.
Publicado: (2022)

Prevalence of BRCA1 and BRCA2 pathogenic and likely pathogenic variants in non-selected ovarian carcinoma patients in Brazil
por: Cotrim, Deborah Porto, et al.
Publicado: (2019)

Prevalence and Spectrum of Germline BRCA1 and BRCA2 Variants of Uncertain Significance in Breast/Ovarian Cancer: Mysterious Signals From the Genome
por: Fanale, Daniele, et al.
Publicado: (2021)

Hereditary breast cancer – a spectrum of pathogenic mutations and unknown variants of BRCA1 and BRCA2 genes in the Czech Republic: efficiency of testing and clinical follow-up
por: Foretova, L, et al.
Publicado: (2005)

Clinical Impact of Pathogenic Variants in DNA Damage Repair Genes beyond BRCA1 and BRCA2 in Breast and Ovarian Cancer Patients
por: Espinel, Whitney, et al.
Publicado: (2022)

Landscape of germline BRCA1/BRCA2 variants in breast and ovarian cancer in Peru
por: Ferreyra, Yomali, et al.
Publicado: (2023)

Prevalence of BRCA1 and BRCA2 pathogenic sequence variants in ovarian cancer patients in the Gulf region: the PREDICT study
por: Azribi, Fathi, et al.
Publicado: (2021)

Correction: Evaluation of copy-number variants as modifiers of breast and ovarian cancer risk for BRCA1 pathogenic variant carriers
por: Walker, Logan C., et al.
Publicado: (2018)

Prevalence of specific and recurrent/founder pathogenic variants in BRCA genes in breast and ovarian cancer in North Africa
por: ElBiad, Oubaida, et al.
Publicado: (2022)

Erratum: Prevalence and Spectrum of Germline BRCA1 and BRCA2 Variants of Uncertain Significance in Breast/Ovarian Cancer: Mysterious Signals From the Genome
Publicado: (2022)

BRCA1/BRCA2 Pathogenic Variant Breast Cancer: Treatment and Prevention Strategies
por: Lee, Anbok, et al.
Publicado: (2020)

GEMO, a National Resource to Study Genetic Modifiers of Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Pathogenic Variant Carriers
por: Lesueur, Fabienne, et al.
Publicado: (2018)

Identifying sequence variants contributing to hereditary breast and ovarian cancer in BRCA1 and BRCA2 negative breast and ovarian cancer patients
por: Jarhelle, Elisabeth, et al.
Publicado: (2019)

Computational and biophysical determination of pathogenicity of variants of unknown significance in cardiac thin filament
por: Mason, Allison B., et al.
Publicado: (2021)

Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriers
por: Hakkaart, Christopher, et al.
Publicado: (2022)

Management Strategies of Breast Cancer Patients with BRCA1 and BRCA2 Pathogenic Germline Variants
por: Edaily, Sarah, et al.
Publicado: (2022)

Novel BRCA1 and BRCA2 pathogenic mutations in Slovene hereditary breast and ovarian cancer families
por: NOVAKOVIĆ, SRDJAN, et al.
Publicado: (2012)

BRCA1 and BRCA2 Unclassified Variants and Missense Polymorphisms in Algerian Breast/Ovarian Cancer Families
por: Cherbal, Farid, et al.
Publicado: (2012)

Sequence Variants of BRCA1 and BRCA2 Genes in Four Iranian Families with Breast and Ovarian Cancer
por: Keshavarzi, F, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_eje8h7th8bq5ag93ppu61i7ds8